$FTRE

Thakral Anshul sold $1.9M of FTRE

Thakral Anshul (Chief Executive Officer) sold 99,869 shares of Fortrea Holdings Inc. (FTRE) at an average of $19.16 ($19.03–$19.28, $1.91M total) across 2 trades on 2026-08-05.

Original reporting
SEC EDGAR · Thakral Anshul
Published Aug 6, 2026, 4:00 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 7, 2026, 7:46 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$FTRE
Neutral
medium confidence
Mentioned
$FTRE
Relevance
6/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$FTRENeutralLow
01

Why it matters

The CEO’s open-market sale is new information for traders monitoring insider activity, but it is not accompanied by any new company performance, guidance, or strategic event.

02

Market read

Traders may briefly reassess sentiment around insider selling, but there is no fundamental catalyst in the filing text.

03

What to watch

The filing does not provide intent, tax context, or whether sales were part of broader compensation/vesting activity; without that, price impact should be discounted.

Relevance 6/10Novelty 5/10Timing: SEC Form 4 filed Aug 6, covering Aug 5 sales

Background

The article is an SEC Form 4 insider transaction disclosure for Fortrea Holdings Inc.

Company-level read

Ticker impact

$FTRENeutralMedium confidence
Context

Fortrea CEO Thakral Anshul sold about 99,869 shares in open-market trades totaling $1.91M, per a new SEC Form 4 filed Aug 6.

Expected impact

Likely limited near-term impact; any effect is more sentiment-driven than fundamental.

Evidence & confidence

This is a routine Form 4 insider transaction with no 10b5-1 plan stated, but the article provides no accompanying operational or guidance change.

Market effects

Minimal, as the disclosure is company-specific and does not indicate sector-wide regulatory or demand changes.

None indicated; the event is an insider transaction in a US-listed issuer.

None indicated; no cross-border deal, contract, or regulatory action is described.

Counterpoint

Insider sales can be driven by diversification, taxes, or pre-planned liquidity needs, so the signal may be overstated versus the lack of a stated 10b5-1 plan.

Key entities

  • Fortrea Holdings Inc.

    Subject of the Form 4 insider transaction disclosure.

  • Thakral Anshul

    Fortrea CEO and reporting person who sold shares.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$FTREMed

Fortrea (FTRE) Stock Is Up, What You Need To Know

Fortrea Holdings (FTRE) shares rose 2.8% after acquiring Worldwide Clinical Trials' Early Phase Services division, expanding its clinical research capabilities. The acquisition includes facilities in Texas. Fortrea's stock is volatile, with a 52-week high of $20.70. Q3 revenue was $701.3M, beating estimates, but earnings missed. Full-year revenue guidance was raised to $2.73B.

$FTREHigh

Fortrea To Acquire Early Phase Services From Worldwide Clinical Trials; Stock Up

Fortrea Holdings (FTRE) agreed to buy the Early Phase Services division of Worldwide Clinical Trials, including labs and clinical units in Texas. The deal expands Fortrea's early development network, adding bioanalytical and clinical pharmacology capabilities. FTRE shares rose 5.98% to $18.78. According to the company, the acquisition supports growth and increases long-term shareholder value.

$FTREMed

Fortrea Holdings Inc: Fortrea to Acquire Clinical Pharmacology Unit and Bioanalytical Laboratory Operations from Worldwide Clinical Trials

Fortrea (FTRE) will acquire Worldwide Clinical Trials' Early Phase Services division for $45M, including a bioanalytical lab and clinical pharmacology unit. The deal expands Fortrea's early clinical development capabilities, enhancing its platform for Phases I-IV studies. Worldwide will focus on its late-stage business. The transaction is subject to regulatory approvals.